Polar Asset Management Partners Inc. Sells 681,872 Shares of NKGen Biotech, Inc. (NYSE:NKGN)

Polar Asset Management Partners Inc. decreased its holdings in NKGen Biotech, Inc. (NYSE:NKGN) by 57.7% in the 4th quarter, HoldingsChannel reports. The firm owned 500,000 shares of the company’s stock after selling 681,872 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in NKGen Biotech were worth $328,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of NKGN. Advisory Research Inc. bought a new position in shares of NKGen Biotech in the fourth quarter worth about $28,000. Geode Capital Management LLC increased its holdings in shares of NKGen Biotech by 12.8% in the fourth quarter. Geode Capital Management LLC now owns 127,168 shares of the company’s stock valued at $83,000 after purchasing an additional 14,454 shares in the last quarter. Kepos Capital LP bought a new position in NKGen Biotech in the 4th quarter worth approximately $151,000. Magnetar Financial LLC acquired a new position in NKGen Biotech during the 4th quarter worth $175,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in NKGen Biotech by 126.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock worth $102,000 after buying an additional 87,000 shares in the last quarter. Institutional investors and hedge funds own 76.17% of the company’s stock.

NKGen Biotech Stock Performance

Shares of NKGN opened at $0.29 on Wednesday. The business’s fifty day moving average price is $0.18 and its two-hundred day moving average price is $0.36. The firm has a market capitalization of $12.81 million, a price-to-earnings ratio of -0.06 and a beta of 0.84. NKGen Biotech, Inc. has a 52 week low of $0.10 and a 52 week high of $1.75.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.